BMS swooped on Karuna towards the end of last year, shortly after AbbVie agreed an $8.7 billion deal to acquire Cerevel Therapeutics, another company developing a schizophrenia drug with a novel ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics in 2023 and the drug's approval last September ended a decades-long drought in new-mechanism therapies for ...

Cobenfy’s launch is tracking against expectations, having surpassed 30,000 total scripts following an FDA approval in late September, according to Lenkowsky. However, a Leerink Partners analysis ...

The United States-based Karuna Foundation has awarded a USD 1 million grant to the Tarayana Foundation to support the construction of disaster-resilient homes for Bhutan’s most vulnerable communities.

An analyst's downbeat new take on Summit Therapeutics (SMMT -3.28%) pushed its stock downward on Hump Day. At the end of Wednesday, the shares had booked a loss of over 11% in price as investors ...

SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell ...

ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment ...

Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth ...

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company"), today issued the following ...

Eli Lilly (LLY) is reportedly nearing a deal to acquire gene editing startup Verve Therapeutics (VERV) for up to $1.3 billion, the Financial Times reported.